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S1038 Journal of Thoracic Oncology Vol. 14 No. 10SBackground: Therapy surveillance is a corner stone in advanced lung
cancer clinical management. Due to the ease of sampling, analysis of
tumor derived circulating DNA in plasma for treatment monitoring and
decision making is desirable. Patients with tumors harboring a sensi-
tizing EGFR mutation benefit from targeted therapy using tyrosine ki-
nase inhibitors (TKIs). Unfortunately, the majority of patients develop
resistance towards the initially administered TKI either through
intrinsic mechanisms of EGFR or mutations of additional genes such as
amplification of MET. Osimertinib can be administered at disease
progression due to the resistance mutation T790M in EGFR. In this
study we used liquid biopsy at progression after TKI treatment to
assess mutational status of sensitizing and T790M mutations. In some
cases, a tumor biopsy was analyzed in parallel as part of clinical
management. Method: Six 10 ml Streck Cell free BCT® tubes were
collected and plasma was isolated. Cell free circulating DNA was pu-
rified and used in an ultra-sensitive ddPCR assay IBSAFE (George et al,
manuscript in preparation). Both the sensitizing EGFR mutation and
T790M was analyzed. In some cases, a solid biopsy was analyzed in the
clinic in parallel to our plasma analysis. Patient outcome data will be
collected from patient files. Result: Eighteen of 25 patients tested
positive in plasma for the previously known sensitizing EGFR mutation
(72%). Twelve of 25 tested positive in plasma for T790M mutation
(48%). Among plasma samples positive for the sensitizing mutation,
67% were also positive for T790M. The minor allele frequency (MAF)
fraction of T790M in comparison to the sensitizing mutation varied
extensively from 0.01% to 90% and also the MAF compared to total
DNA varied (0.005% to 23%). Updated clinical follow up data will be
presented. Conclusion: For a subset of patients were a tumor biopsy is
not feasible, a liquid biopsy could provide information about the
mutational status. As the MAF vary considerably and can be very low, a
highly sensitive assay such as the IBSAFE ddPCR assay, capable of
confirming a mutation at a MAF as low as 0.005% is advantageous.
Further, a large plasma input volume may aid in identifying patients
positive for mutations at a low MAF. Updated clinical follow up data
will be discussed. Keywords: plasma, EGFR, ddPCR
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Background: The majority of patients with epidermal growth factor
receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC)
develop resistance to first- or second-generation EGFR-tyrosine kinase
inhibitor (TKI) after a median treatment period of 12 months. This
study aimed to determine the prevalence and predictors of acquired
T790M mutation as a resistance mechanism among these patients.
Method: This was a retrospective study of patients with sensitising
EGFR-mutant advanced NSCLC who experienced disease progression
(PD) while on first- or second-generation EGFR-TKI treatment and
underwent investigations to determine the resistance mechanisms in
University of Malaya Medical Centre from 1st January 2015 to 31st
December 2017. Result: Of 87 patients, acquired T790M mutation was
detected in 55 (63.2%) patients at PD. T790M mutation was signifi-
cantly more frequent in patients who achieved partial response (PR) asthe best response (p ¼ 0.008) or had new lung metastasis (p ¼ 0.048);
and significantly less frequent in patients who developed new symp-
tomatic brain metastases (p ¼ 0.021). Patients with exon 19 deletion
were more likely to acquire T790M mutation compared to those with
exon 21 L858R point mutation (p ¼ 0.077). In multivariate analysis, PR
with EGFR-TKI treatment was a significant independent predictor of
acquired T790M mutation (p ¼ 0.021) while having new symptomatic
brain metastases (p ¼ 0.034) or new lymph node metastases (p ¼
0.038) were significant independent predictors against acquired T790M
mutation. Conclusion: Acquired T790M mutation was a common
resistance mechanism leading to first- or second-generation EGFR-TKI
treatment failure. Patients with tumours harbouring exon 19 deletion
mutation were more likely to acquire T790M mutation. A best tumour
response of PR to EGFR-TKI treatment was an independent predictor of
acquiring this resistance. This information is helpful to clinicians in the
early prognostication and management planning for patients with
EGFR-mutant NSCLC. Keywords: EGFR-TKI, T790M mutation, Acquired
resistance
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Background: Several studies have shown that NSCLC genomic back-
ground among Hispanics differs from other populations, therefore gen-
otyping tumors in order to assess their molecular profile is adamantly
needed in the current era of targeted therapy. Panel-detected oncodriver
mutations can drive therapeutic approaches, and can help classify the
information in order to propose strong evidence-based interventions in
treatment guidelines. In this study we sought to understand the land-
scape of genomic drivers in a cohort of patients with lung adenocarci-
noma of Hispanic ancestry. Method: Tumor samples were collected
from 48 patients with lung adenocarcinoma from march 2017 until
march 2019. Samples were submitted for testing to Foundation Medi-
cine and hybrid capture NGS was performed.
